F-group (family)
323.1.1.5 Condensation
Ligands and drugs
712
Member domains
171
with ligand contacts (≤ 4 Å)
24.0% of members
108
with DrugDomain annotations
15.2% of members
78
with a DrugBank compound
11.0% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 323.1.1.5 belongs to X-group 323 CoA-dependent acyltransferases, which binds 9.6 ligand superclasses per 20 proteins, broader than 90% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03912 | PNS | D-pantetheine 4'-phosphate | 29 |
| DB02910 | CO8 | Octanoyl-Coenzyme A | 6 |
| DB02219 | CXS | 3-(cyclohexylamino)propanesulfonic acid | 1 |
| DB02418 | BU9 | (R,R)-2,3-Butanediol | 1 |
| DB02579 | AKR | Acrylic Acid | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| PNS | 4'-PHOSPHOPANTETHEINE | 40 |
| CL | CHLORIDE ION | 14 |
| NAmetal | SODIUM ION | 14 |
| 868 | S-[2-[3-[[(2S)-3,3-dimethyl-2-oxidanyl-4-phosphonooxy-butanoyl]amino]propanoylamino]ethyl] (2R)-2-azanylpropanethioate | 8 |
| JQG | (2~{R})-~{N}-[3-[2-[[(2~{S})-2-formamido-3-methyl-butanoyl]amino]ethylamino]-3-oxidanylidene-propyl]-3,3-dimethyl-2-oxidanyl-4-[oxidanyl-bis(oxidanylidene)-$l^{6}-phosphanyl]oxy-butanamide | 8 |
| CO8 | OCTANOYL-COENZYME A | 6 |
| Kmetal | POTASSIUM ION | 5 |
| 2GH | N~3~-[(2R)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-N-pentyl-beta-alaninamide | 4 |
| 4T7 | (1R)-1-(naphthalen-2-yl)ethane-1,2-diol | 4 |
| 5FQ | N-pentyl-L-alaninamide | 4 |
| A1AN1 | (7S,10aR)-1-methyl-4-{4-[(5R)-1,1,5-trihydroxy-4,4-dimethyl-1,6,11-trioxo-2-oxa-7,10-diaza-1lambda~5~-phosphadodecan-12-yl]phenyl}-3,5,6,7,8,9,10,10a-octahydrocycloocta[d]pyridazin-7-yl [2-({N-[(2R)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl]carbamate | 4 |
| UM2 | (2S)-2-amino-N-butyl-propanamide | 4 |
| A1AMN | N-formyl-L-valyl-N-[2-({N-[(2S)-2-hydroxy-4-{[(S)-hydroxy(oxo)-lambda~5~-phosphanyl]oxy}-3,3-dimethylbutanoyl]-beta-alanyl}amino)ethyl]glycinamide | 3 |
| A1AMO | N-[2-(glycylamino)ethyl]-N~3~-[(2S)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alaninamide | 3 |
| IOD | IODIDE ION | 3 |
| PG0 | 2-(2-METHOXYETHOXY)ETHANOL | 3 |
| SAL | 2-HYDROXYBENZOIC ACID | 3 |
| 9EF | N-[2-(acetylamino)ethyl]-N~3~-[(2R)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alaninamide | 2 |
| A1AN7 | (7S,10aR)-1-methyl-4-{4-[(5R)-1,1,5-trihydroxy-4,4-dimethyl-1,6,10,15-tetraoxo-2-oxa-7,11,14-triaza-1lambda~5~-phosphahexadecan-16-yl]phenyl}-3,5,6,7,8,9,10,10a-octahydrocycloocta[d]pyridazin-7-yl [(5R)-1,1,5-trihydroxy-4,4-dimethyl-1,6,10-trioxo-2-oxa-7,11-diaza-1lambda~5~-phosphatridecan-13-yl]carbamate (non-preferred name) | 2 |
| FGU | S-(2-acetamidoethyl) (2S)-2-azanyl-4-methyl-pentanethioate | 2 |